Cingulate (CING) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cingulate (CING) has outperformed Rein Therapeutics (RNTX) over the past year, gaining 17.3% versus a loss of 45.2%. Cingulate is the larger company by market cap ($70.8 million vs $68.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | RNTX |
|---|---|---|
| Share price | $4.87 | $0.7887 |
| Market cap | $70.82M | $68.04M |
| 1-day change | -0.41% | -4.40% |
| YTD return | +12.21% | -32.01% |
| 1-year return | +17.35% | -45.23% |
| 5-year return | — | -96.10% |
| EPS (TTM) | $-3.51 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.89 | $2.18 |
| 52-week low | $3.16 | $0.694 |
| Distance from 52-week high | -59.04% | -63.82% |
| Average volume | 150.39K | 427.95K |
| Shares outstanding | 14.54M | 86.27M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed RNTX by 62.6 percentage points over the past year.
CING vs RNTX FAQ
Which is bigger, Cingulate or Rein Therapeutics?
Cingulate (CING) is larger, with a market capitalization of $70.82M compared with $68.04M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, CING or RNTX?
CING returned +17.35% over the past 12 months, compared with -45.23% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.